Clinical human trials begin for COVID-19 vaccine in China

[aliaselin]

https://twitter.com/x/status/1374677438962221059

Clover Biopharmaceuticals @CloverBiopharma

Today, we are happy to announce the launch of our Phase 2/3 #ClinicalTrial, SPECTRA, with the dosing of our first participants. The goal of this study is to further test the efficacy, safety and immunogenicity of our S-Trimmer COVID-19 vaccine.
Learn more: https://prn.to/3scB7Db


7:00 PM · Mar 24, 2021

This vaccine will done the clinical trail in Europe. Maybe the only one we will sold in Europe

 

[JSCh]

https://twitter.com/x/status/1375991029887692802

 

[JSCh]

https://twitter.com/x/status/1377800135535591425

Global Times @globaltimesnews
China state-affiliated media

Sinovac on Fri said the third production line of its #COVID19 #vaccine was completed and put into use, achieving an annual capacity of 2 billion doses. Over 200m vaccine doses have been delivered to over 20 countries; it is estimated that over 100m doses have been administered.


9:48 AM · Apr 2, 2021

 

[JSCh]

https://twitter.com/x/status/1381291000174350339

Global Times @globaltimesnews
China state-affiliated media

Closer collaboration on the studies could provide reference for China as the domestically-produced CanSino vaccine is also an adenovirus vector shot, although no serious side effects have been observed so far. https://bit.ly/3dSq1NB


1:00 AM · Apr 12, 2021

 

[JSCh]

China’s 2nd protein subunit COVID-19 vaccine to enter clinical trials, easy to mass produce
By Hu Yuwei
Published: Feb 23, 2021 08:43 PM

Sinopharm's COVID-19 vaccine. Photo: VCG​

China's COVID-19 protein subunit vaccines have reported encouraging progress as a leading Chinese vaccine producer, Sinopharm, plans to bring its newly developed recombinant subunit vaccine candidate into clinical trials.

Sinopharm's vaccine is the second protein subunit vaccine in the country after one developed by China's Anhui Zhifei Longcom Biopharmaceutical Co, which started late-stage trials in Pakistan upon approval on Sunday.

The protein subunit vaccine is expected to perform better than the inactivated vaccines, and would be easier to mass produce, Sinopharm Chairman Liu Jingzhen suggested in a recent interview with China Central Television (CCTV).

Liu said its second COVID-19 inactivated vaccine - developed by subsidiary Wuhan Institute of Biological Products - is now applying for conditional approval for mass use.

China's first recombinant subunit COVID-19 vaccine, co-developed by Zhifei and the Institute of Microbiology of the Chinese Academy of Sciences (IMCAS), has been approved to enter phase III clinical trials in Pakistan.

The double-blinded, placebo-controlled trials will involve around 10,000 participants in Pakistan, of whom 30 percent will be seniors, according to news released by IMCAS on Sunday.

Experts said the recombinant subunit vaccine can be an important addition to the two Chinese inactivated vaccines already in mass production, considering its shorter production process.

"Traditional inactivated vaccines normally take several months to develop, and require biosafety level 3 labs for production. Meanwhile, access to the recombinant protein vaccine is easier, and the biotechnology is more mature than the mRNA and adenovirus-vector techniques used in some available vaccines," Zhuang Shilihe, a Guangzhou-based doctor closely studying the COVID-19 vaccines, told the Global Times on Tuesday.

Novavax, a US-based pharmaceutical company that developed a similar protein-based COVID-19 vaccine, reported an efficacy rate of 89.3 percent in its phase III clinical trials conducted in the UK in early February, boosting global confidence in this type of technical innovation.

Zhuang believes that protein subunit COVID-19 vaccines can perform better against new COVID-19 variants, as lab research found these new vaccines remain effective in triggering an immune response.

In a pre-print published on biology server BioRXIV on February 2, Gao Fu, director of the Chinese Center for Disease Control and Prevention, revealed that Zhifei's recombinant protein vaccine was still effective against the South African variant, although its efficacy was reduced by 1.6 times, which is within acceptable parameters. In particular, it was advantageous in comparison to the mRNA vaccine, leading with a reduction of three to eight times more.

Giving these promising signs, Uzbekistan's government has decided to purchase 1 million doses of Zhifei's vaccine and start voluntary mass vaccination, media reported.

Uzbekistan will almost double the number of volunteers from 5,000 to 9,000 involved in a phase III trial, the Uzbek Ministry of Innovative Development said in early February.

https://twitter.com/x/status/1381440893291393026

 

[8888888888888]

the inactive vaccines are the best due to the virus being mutation happy, pity it take a long time to create.

 

[JSCh]

08:26, 18-Feb-2021
Sinovac vaccine works on UK, South African variants, says Brazil institute
CGTN

The COVID-19 vaccine developed by China's Sinovac Biotech is effective against the UK and South African variants, the vaccine's Brazilian partner said on Wednesday, citing test results in Chinese trials.

"We have tested this vaccine in China against the English and the South African variants, with good results," said Dimas Covas, head of the Butantan biomedical center in Sao Paulo, which leads domestic trials of the Chinese vaccine and is supplying doses to Brazil's Health Ministry.
Covas did not give any more details on exactly how effective the vaccine proved against these strains.

Butantan is also testing the vaccine, known as CoronaVac, against the Brazilian variant of the virus which appeared in the city of Manaus, he said.

"Soon we will have the results and we are very positive it will do the job," Covas said.

Covas was speaking at a news conference in the small city of Serrana, in the interior of Sao Paulo state, where Butantan began a mass vaccination campaign on Wednesday aimed at inoculating the entire adult population against COVID-19 to test whether it lowers the infection rate.

Source(s): Reuters

https://twitter.com/x/status/1362190166689943553

https://twitter.com/x/status/1381529037273587712

 

[JSCh]

https://twitter.com/x/status/1381291000174350339

Global Times @globaltimesnews
China state-affiliated media

Closer collaboration on the studies could provide reference for China as the domestically-produced CanSino vaccine is also an adenovirus vector shot, although no serious side effects have been observed so far. https://bit.ly/3dSq1NB


1:00 AM · Apr 12, 2021

https://twitter.com/x/status/1382280010883592194

Reuters Health @Reuters_Health

China's CanSino Biologics Inc said on Wednesday that no serious blood clot cases had been reported so far in people who were injected with its COVID-19 vaccine Ad5-nCoV.

China's CanSinoBIO says no blood clots reported from its COVID-19 shot​

China's CanSino Biologics Inc said on Wednesday that no serious blood clot cases had been reported so far in people who were injected with its COVID-19 vaccine Ad5-nCoV.​

reuters.com​

​

6:30 PM · Apr 14, 2021

 

[JSCh]

China starts building COVID-19 vaccine production facility
Source: Xinhua| 2020-12-21 20:29:20|Editor: huaxia

KUNMING, Dec. 21 (Xinhua) -- China started the construction on Monday of a plant for manufacturing an mRNA-based COVID-19 vaccine, with production operations due to begin in eight months, according to local authorities.

The facility in the city of Yuxi, in southwest China's Yunnan Province, is expected to produce 120 million doses per year in its first phase, with key manufacturing equipment and core ingredients all independently developed by China.

The vaccine was approved by the National Medical Products Administration for clinical drug trials on June 19, 2020, and is about to enter phase-II clinical trials.

It was jointly developed by the Academy of Military Medical Sciences, Suzhou Abogen Biosciences and Yunnan-based Walvax Biotechnology Co., Ltd.

In phase-I clinical trials, the vaccine was shown to be safe with good immunogenicity, and it has excellent stability in storage at 2-8 degrees Celsius, according to the vaccine developers.

The mRNA in the vaccine enters human cells and expresses antigens, which induces the immune system to respond so that the body can obtain immunity.

https://twitter.com/x/status/1382506459733327872

China Economy @CE_ChinaEconomy
China state-affiliated media

The first #China-developed #mRNA #COVID19 #vaccine is expected to enter Phase III clinical trials overseas next month, vaccine developer Suzhou Abogen Biosciences confirmed on April 13. Production capacity for the new vaccine could reach some 120 mln doses in 2021.


9:30 AM · Apr 15, 2021

 

[JSCh]

https://twitter.com/x/status/1374677438962221059

Clover Biopharmaceuticals @CloverBiopharma

Today, we are happy to announce the launch of our Phase 2/3 #ClinicalTrial, SPECTRA, with the dosing of our first participants. The goal of this study is to further test the efficacy, safety and immunogenicity of our S-Trimmer COVID-19 vaccine.
Learn more: https://prn.to/3scB7Db


7:00 PM · Mar 24, 2021

https://twitter.com/x/status/1384787741045448706

People's Daily, China @PDChina
China state-affiliated media

#Brazil's Health Regulatory Agency (Anvisa) on Monday authorized Phase II and III clinical trials of a new #COVID19 #vaccine developed by China’s Sichuan Clover Biopharmaceuticals. The Chinese company plans to test the vaccine on 12,100 Brazilian volunteers aged over 18 yrs old.


4:35 PM · Apr 21, 2021

 

[JSCh]

https://twitter.com/x/status/1387371678968074245

Hilda Bastian, PhD @hildabast

Results from @butantanoficial study aren't expected before late May, but the city of Serrana is reporting a big drop in Covid-19 & hospitalization (Need the study to know how much credit to give to vaccination) 1/2 https://g1.globo.com/sp/ribeirao-preto-franca/noticia/2021/04/23/vacinacao-em-massa-media-movel-de-casos-da-covid-19-se-mantem-em-queda-ha-1-mes-em-serrana-sp.ghtml

 

[JSCh]

Good news, long thread on Sinopharm assessment from WHO, please click and read in Twitter if want to know more.

https://twitter.com/x/status/1389213279935889408

Hilda Bastian, PhD @hildabast

The evidence assessments - but not the WHO decisions - for Sinopharm's Beijing vax & Sinovac's CoronaVac are going up on the WHO website https://who.int/news-room/events/detail/2021/04/29/default-calendar/extraordinary-meeting-of-the-strategic-advisory-group-of-experts-on-immunization-(sage)-29-april-2021… HT @lutl88 @hvasquezhg ...1/n

...Sinopharm Beijing: WHO assessment. 45,000-participant trial in UAE/Bahrain/Egypt/Jordan, doses 21 days apart, efficacy:

- Overall: 78.1% (CI 65-86)
- For people with no previous infection: 80.8% (67-89) (the usual efficacy rate for others)

https://cdn.who.int/media/docs/default-source/immunization/sage/2021/april/2_sage29apr2021_critical-evidence_sinopharm.pdf?sfvrsn=3dfe32c1_5… ...2/n

9:40 PM · May 3, 2021

 

[JSCh]

11:13, 04-May-2021
Pakistan to locally produce China's CanSino COVID-19 vaccine
CGTN

A group of products with logo of CanSinoBIO. /CFP​

The local production of China's single-dose CanSino COVID-19 vaccine is set to commence in Pakistan to facilitate its vaccination drive, said Special Assistant to the Pakistani Prime Minister on Health Faisal Sultan on Monday.

Thanking China for supporting Pakistan in its fight against the COVID-19 pandemic, Sultan told local media that China remains a strong partner which had donated vaccines and other supplies and is also transferring technology of vaccine production to Pakistan. The start of the local production of the CanSino vaccine will gradually make Pakistan largely self-sufficient in meeting its COVID-19 vaccine needs.

Sultan also expressed that out of 100 million people eligible for vaccination in the country, the government aimed to vaccinate 70 million by the end of 2021, adding that currently, Pakistan is vaccinating nearly 150,000 people every day, while the government is making efforts to reach a target of 300,000 vaccinations daily.

Pakistan has a population of 220 million and over 2.5 million people have already been vaccinated owing to the proactive strategy of the government for vaccine procurement, the official said. Urging people to continue to observe the Standard Operating Procedures (SOPs) to stop the spread of the virus, said Sultan, adding "vaccines are very important to prevent the virus from spreading, but what is even more important is following SOPs."

According to Pakistan's National Command and Operation Center, the country had reported 834,146 confirmed cases with 18,149 deaths and 728,044 recoveries as of Sunday.

Source(s): Xinhua News Agency

said Sultan, adding "vaccines are very important to prevent the virus from spreading, but what is even more important is following SOPs."

I think this is wise, all the gov't that think they are smarter than the virus has live to regret it. All the best to Pakistan.

 

[JSCh]

https://twitter.com/x/status/1389406725514555392

CGTN @CGTNOfficial
China state-affiliated media

Chinese pharmaceutical giant Sinopharm will jointly produce its COVID-19 vaccine with Argentine companies, the Chinese Embassy in #Argentina said on Monday. Two sides are discussing technical details of producing the #vaccines and will start the process as soon as possible


10:29 AM · May 4, 2021

 

[JSCh]

https://twitter.com/x/status/1390704527972708364

World Health Organization (WHO) @WHO

WHO today listed the Sinopharm #COVID19 vaccine for emergency use in all countries, a prerequisite for a potential #COVAXroll-out. Interim policy recommendations were also issued for the vaccine usage.

https://bit.ly/3ba9dRO


12:24 AM · May 8, 2021